Please use a PC Browser to access Register-Tadawul
Lexicon Pharmaceuticals, Jeffrey Wade Determine His Employment As President And COO Would Terminate As Of September 30, 2024 - Filing
Lexicon Pharmaceuticals, Inc. LXRX | 0.00 |
On September 13, 2024, the company and Jeffrey L. Wade determined that his employment as president and chief operating officer (in which capacity, Mr. Wade has functioned as principal financial officer) would terminate as of September 30, 2024.
Effective as of the date of termination of Wade’s employment, Kristen L. Alexander will assume the function of principal financial officer.
Also in connection with the termination of his employment, the company entered into a consulting agreement with Wade on September 13, 2024 pursuant to which he will provide his consulting and advisory services for a period of eight months following the date of his termination of employment and the company will pay Wade fees of $3,000 per month.